Cathomas, Richard; Rothermundt, Christian; Klingbiel, Dirk; Bubendorf, Lukas; Jaggi, Rolf; Betticher, Daniel C; Brauchli, Peter; Cotting, Denise; Droege, Cornelia; Winterhalder, Ralph; Siciliano, Daniele; Berthold, Dominik R; Pless, Miklos; Schiess, Ralph; von Moos, Roger; Gillessen, Silke (2012). Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clinical cancer research, 18(21), pp. 6049-57. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-2219
Full text not available from this repository. (Request a copy)The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pathologie > Forschungsgruppe Molekularbiologie |
UniBE Contributor: |
Jaggi, Rolf |
ISSN: |
1078-0432 |
Publisher: |
American Association for Cancer Research |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:37 |
Last Modified: |
05 Dec 2022 14:11 |
Publisher DOI: |
10.1158/1078-0432.CCR-12-2219 |
PubMed ID: |
22977195 |
Web of Science ID: |
000312020400024 |
URI: |
https://boris.unibe.ch/id/eprint/15064 (FactScience: 222227) |
Actions (login required)
 |
Edit item |